Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 5, 2014, Pages 674-677

  Hill, D A ^a,b   Siracusa, M C ^b   Ruymann, K R ^a   Tait Wojno, E D ^b   Artis, David ^b,c   Spergel, Jonathan M ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

allergy; asthma; basophil; IgE; omalizumab

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB; ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; ASTHMA; BASOPHIL; CELL POPULATION; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; BLOOD; COMPLICATION; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; TREATMENT OUTCOME;

ADOLESCENT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, SURFACE; ASTHMA; BASOPHILS; CHILD; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MALE; OMALIZUMAB; TREATMENT OUTCOME;

EID: 84898484148     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12375     Document Type: Article

References (12)

1. Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, et al. National surveillance for asthma-united states, 1980-2004. MMWR Surveill Summ 2007; 56: 1-54.
2. Siracusa MC, Comeau MR, Artis D,. New insights into basophil biology: Initiators, regulators, and effectors of type 2 inflammation. Ann N Y Acad Sci 2011; 1217: 166-177.
3. Lichtenstein LM, Bochner BS,. The role of basophils in asthma. Ann N Y Acad Sci 1991; 629: 48-61.
4. Burton OT, Oettgen HC,. Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases. Immunol Rev 2011; 242: 128-143.
5. Hill DA, Siracusa MC, Abt MC, Kim BS, Kobuley D, Kubo M, et al. Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. Nat Med 2012; 18: 538-546.
6. Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 study group. N Engl J Med 1999; 341: 1966-1973.
7. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.
8. Eckman JA, Sterba PM, Kelly D, Alexander V, Liu MC, Bochner BS, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol. 2010; 125: 889, 895.
9. Saini SS, Macglashan DW, Jr. Assessing basophil functional measures during monoclonal anti-IgE therapy. J Immunol Methods 2012; 383: 60-64.
10. Macglashan DW Jr, Saini SS,. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation. J Allergy Clin Immunol 2013; 132: 906-911.
11. Noga O, Hanf G, Kunkel G, Kleine-Tebbe J,. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol 2008; 146: 66-70.
12. Kepley CL, Craig SS, Schwartz LB,. Identification and partial characterization of a unique marker for human basophils. J Immunol 1995; 154: 6548-6555.